The stock of Protalix BioTherapeutics Inc (PLX) has gone down by -6.41% for the week, with a -17.98% drop in the past month and a 19.67% rise in the past quarter. The volatility ratio for the week is 4.35%, and the volatility levels for the past 30 days are 4.36% for PLX. The simple moving average for the past 20 days is -7.20% for PLX’s stock, with a 45.62% simple moving average for the past 200 days.
Is It Worth Investing in Protalix BioTherapeutics Inc (AMEX: PLX) Right Now?
The stock has a 36-month beta value of 0.54. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PLX is 68.07M, and at present, short sellers hold a 7.42% of that float. On March 14, 2025, the average trading volume of PLX was 623.46K shares.
PLX) stock’s latest price update
Protalix BioTherapeutics Inc (AMEX: PLX) has experienced a rise in its stock price by 0.92 compared to its previous closing price of 2.17. However, the company has seen a fall of -6.41% in its stock price over the last five trading days. proactiveinvestors.com reported 2025-02-24 that For a small biotech company, Protalix Biotherapeutics Inc (NYSE-A:PLX) is making a big impression with analysts and investors by targeting rare diseases with cutting-edge treatments. The New Jersey- and Israel-based company has emerged as a biotech underdog with strong tailwinds that analysts at HC Wainwright and Zacks Small Cap Research believe puts it the brink of sustainable profitability.
Analysts’ Opinion of PLX
Many brokerage firms have already submitted their reports for PLX stocks, with H.C. Wainwright repeating the rating for PLX by listing it as a “Buy.” The predicted price for PLX in the upcoming period, according to H.C. Wainwright is $11 based on the research report published on June 08, 2020 of the previous year 2020.
Rodman & Renshaw, on the other hand, stated in their research note that they expect to see PLX reach a price target of $5, previously predicting the price at $4. The rating they have provided for PLX stocks is “Buy” according to the report published on April 17th, 2017.
Rodman & Renshaw gave a rating of “Buy” to PLX, setting the target price at $3.50 in the report published on April 04th of the previous year.
PLX Trading at -7.11% from the 50-Day Moving Average
After a stumble in the market that brought PLX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -20.65% of loss for the given period.
Volatility was left at 4.36%, however, over the last 30 days, the volatility rate increased by 4.35%, as shares sank -18.23% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +15.08% upper at present.
During the last 5 trading sessions, PLX fell by -7.05%, which changed the moving average for the period of 200-days by +76.83% in comparison to the 20-day moving average, which settled at $2.36. In addition, Protalix BioTherapeutics Inc saw 16.49% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for PLX
Current profitability levels for the company are sitting at:
- -0.2 for the present operating margin
- 0.36 for the gross margin
The net margin for Protalix BioTherapeutics Inc stands at -0.21. The total capital return value is set at -0.24. Equity return is now at value -27.18, with -12.88 for asset returns.
Based on Protalix BioTherapeutics Inc (PLX), the company’s capital structure generated 0.15 points at debt to capital in total, while cash flow to debt ratio is standing at 1.46. The debt to equity ratio resting at 0.18. The interest coverage ratio of the stock is -4.77.
Currently, EBITDA for the company is 11.65 million with net debt to EBITDA at 3.36. When we switch over and look at the enterprise to sales, we see a ratio of 3.1. The receivables turnover for the company is 20.81for trailing twelve months and the total asset turnover is 0.74. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.98.
Conclusion
To sum up, Protalix BioTherapeutics Inc (PLX) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
